Q3 2025 Aker Biomarine ASA Earnings Call Transcript
Key Points
- Aker BioMarine ASA (STU:1PG) reported a 15% year-over-year increase in group revenues, reaching $56.8 million for the quarter.
- The human health ingredients segment showed strong performance with a 23% revenue growth year-over-year, driven by both volume growth and better pricing.
- The company secured a significant new contract for its Superba Krill Oil, expected to contribute positively in Q4 2025.
- Aker BioMarine ASA (STU:1PG) achieved a gross margin of 44%, up from 36% in the same quarter last year, indicating improved operational efficiency.
- The company is well-positioned in the growing omega-3 market, particularly in the krill and algae-based segments, which are expected to grow significantly in the coming years.
- Consumer health products segment experienced a 6% decline in revenue year-over-year, reflecting challenges in the market.
- Emerging business segment reported stable revenues but continued to operate at a loss, with a negative EBITDA of $0.4 million.
- The company faced higher working capital requirements, impacting cash flow from operations, which was only $0.4 million for the quarter.
- Interest-bearing debt increased slightly to $165 million, influenced by higher working capital and payment of the feed ingredient purchase price.
- The protein factory sale process is slow due to market uncertainties, leading to the closure of the factory to minimize cash outflow.
Good morning and welcome to RKB Marin's presentation of the 3rd quarter 2025 where we will present the highlights and the financials of the quarter.
Today it's me, Mat Johnson, the CEO, and the CFO, Katrine Klaveness.
Starting with the highlights.
Yet another strong quarter by Aki Barin. We delivered revenues of $56.8 million. That is up 15% year over year. That is a revenue for the group and a strong development of the group with 50% increase up to $12.2 million for the quarter.
For human health ingredients, another very strong quarter delivered $30.2 million of revenue, 23% growth year over year, and an Ebea of $13.5 million up 35% from the same quarter last year.
Consumer health products delivered revenues of 27.4 million, down 6% year over year, but in line with the last two or three quarters. EBT for the quarter was 1.8 million.
For emerging business, revenues were $2 million stable from the previous quarters within a negative EB of $0.4 million and we also stand a stock released
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
